In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
Abstract Background Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable success in the treatment of hematologic malignancies, while the success has not yet been replicated in solid tumors. To some extent, the disappointing results can be attributed to the paucity and heterogen...
Main Authors: | Zhichen Sun, Rutian Li, Yun Shen, Siyi Tan, Naiqing Ding, Ruihan Xu, Xinyue Wang, Jia Wei, Baorui Liu, Fanyan Meng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-03-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-022-01246-y |
Similar Items
-
Antigen-specific T cell activation independently of the MHC: chimeric antigen receptor (CAR)-redirected T cells.
by: Hinrich eAbken, et al.
Published: (2013-11-01) -
Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
by: Ashley R. Sutherland, et al.
Published: (2020-09-01) -
T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
by: Elien De Bousser, et al.
Published: (2021-12-01) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
by: Cristina Aparicio, et al.
Published: (2021-10-01) -
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
by: Praveen Sridhar, et al.
Published: (2017-07-01)